Next week our patients will all be making their New Year’s resolutions and weight loss will be one that many of them make. After a month of eating everything the holidays have to offer they will all be looking for the holy grail of weight loss and you can bet there will many companies willing to help them. We like to take a more scientific approach and if you check out Items 5, Low Carb Diets Are Okay, and 11, Diabetes Reversed with Investigational Weight Loss Drug, you will get some new information on ways to help your patients. With obesity increasingly out of hand Item 5 brings us information that the ADA is finally renewing their approval of low carb diets for diabetes patients.
Even with all this data we have really only seen one class of drugs that have proven weight loss abilities, the GLP-1analogs. In order to reaffirm the fact that it isn’t just the nausea that results in weight loss I have looked back at research and found a study from the American Journal of Clinical Nutrition that shows that Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. While you are perusing through this article be sure to check out figures 1 and 2 to quickly see how well these analogs can work.
NEW CME available! 13 AMA PRA Category 1 Credits are now available from CardioCareLive. See our CME page for all of CardioCareLive’s enduring CME available.
Topics: One of the country’s largest health organizations conducts a groundbreaking study on how media can improve diabetes control. Also, how hormones help and hinder diabetes. Sundays on CNBC at 7 PM ET, 6 PM CT, and 4 PM PT. Catch up on dLife.com.
Please answer this week’s poll: Which is the most important goal of pharmacologic treatment along with lifestyle change for T2DM patients?
Check out this week’s “Test Your Diabetes Knowledge” question!
Dave Joffe, Editor-in-chief